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Abstract
Airway inflammation is a major contributing factor in both asthma and chronic obstructive pulmonary disease (COPD) and 
represents an important target for treatment. Inhaled corticosteroids (ICS) as monotherapy or in combination therapy with 
long-acting β2-agonists or long-acting muscarinic antagonists are used extensively in the treatment of asthma and COPD. 
The development of ICS for their anti-inflammatory properties progressed through efforts to increase topical potency and 
minimise systemic potency and through advances in inhaled delivery technology. Budesonide is a potent, non-halogenated 
ICS that was developed in the early 1970s and is now one of the most widely used lung medicines worldwide. Inhaled bude-
sonide’s physiochemical and pharmacokinetic/pharmacodynamic properties allow it to reach a rapid and high airway efficacy 
due to its more balanced relationship between water solubility and lipophilicity. When absorbed from the airways and lung 
tissue, its moderate lipophilicity shortens systemic exposure, and its unique property of intracellular esterification acts like 
a sustained release mechanism within airway tissues, contributing to its airway selectivity and a low risk of adverse events. 
There is a large volume of clinical evidence supporting the efficacy and safety of budesonide, both alone and in combination 
with the fast- and long-acting β2-agonist formoterol, as maintenance therapy in patients with asthma and with COPD. The 
combination of budesonide/formoterol can also be used as an as-needed reliever with anti-inflammatory properties, with 
or without regular maintenance for asthma, a novel approach that is already approved by some country-specific regulatory 
authorities and currently recommended in the Global Initiative for Asthma (GINA) guidelines. Budesonide remains one 
of the most well-established and versatile of the inhaled anti-inflammatory drugs. This narrative review provides a clinical 
reappraisal of the benefit:risk profile of budesonide in the management of asthma and COPD.
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1 Introduction
Chronic airway inflammation is a characteristic feature of 
asthma and chronic obstructive pulmonary disease (COPD), 
and is therefore an important target for treatment [1, 2]. Use 
of glucocorticosteroids (corticosteroids) has been investi-
gated in both conditions [3–7], with the first successful treat-
ment of asthma with an oral corticosteroid (OCS) reported in 
1950 [3, 8]. However, although highly effective, long-term 
use of OCS was soon found to be associated with serious 
adverse effects, including osteoporosis, diabetes, Cushing’s 
syndrome, acne, skin thinning and bruising [8].
Following early trials of inhalation with various dermal 
hydrocortisone formulations [9, 10], second-and third-gener-
ation dermal steroids were developed by medicinal chemists 
who focused on increasing potency through addition of the 
halogens chlorine or fluorine [11], leading to the first suc-
cessful inhaled corticosteroid for the treatment of asthma in 
1972: beclomet(h)asone dipropionate (BDP) [5]. However, 
BDP was selected on the basis of its high topical efficacy 
on the skin and was not specifically optimised to reduce its 
systemic risks when absorbed via other routes. In contrast, 
given the known systemic side effect liability of second- and 
third-generation halogenated steroids, budesonide (devel-
oped in the same period as the BDP inhalation findings) 
was screened primarily for improved topical selectivity [12, 
13]. Budesonide was found to have a better topical selec-
tivity than that of BDP, fluocinolone acetonide, flunisolide 
(FLU) and triamcinolone acetonide (TA) [12, 13]. Thus, 
budesonide was the first topical corticosteroid selected for 
improved local selectivity, and its rapid uptake into tissue 
made it a good prospect for inhalation therapy. This was the 
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Key Points 
Inhaled corticosteroids are the cornerstone of current 
treatment for asthma and are also widely used in com-
bination with a long-acting β2-agonist with or without 
a long-acting muscarinic antagonist in the management 
of patients with moderate-to-severe chronic obstructive 
pulmonary disease.
Budesonide is a long-established inhaled corticosteroid 
and its unique molecular structure and pharmacokinetic/
pharmacodynamic properties underpin its rapid efficacy 
and favourable safety profile.
Budesonide may be used as maintenance therapy in 
patients with moderate-to-severe asthma and is recom-
mended in global asthma management guidelines for use 
in combination with the bronchodilator formoterol as an 
as-needed reliever with anti-inflammatory properties, 
with or without regular maintenance therapy.
severe COPD at high risk of exacerbations, since this com-
bination improves both symptoms and lung function and 
reduces exacerbation risk [21].
In this narrative review, based on the authors’ collective 
expertise, we provide a clinical reappraisal of the benefit:risk 
profile of budesonide in the management of asthma and 
COPD, after a brief overview of the pharmacodynamics of 
ICS.
2  Brief Overview of Inhaled Corticosteroids 
(ICS) Pharmacodynamics
2.1  Mechanisms of Action of ICS in Asthma 
and Chronic Obstructive Pulmonary Disease 
(COPD)
ICS diffuse through cell membranes and subsequently bind 
to the glucocorticoid receptor (GCR). The GCR, which is 
believed to share a common ancestral receptor type with 
the mineralocorticoid and progesterone receptors (MR 
and PR), is present in the cytoplasm of most human cell 
types, bound to HSP90 chaperone proteins [22–24]. Bind-
ing results in dissociation of HSP90 and formation of an 
activated GCR–corticosteroid complex. Subsequent translo-
cation across the nuclear membrane, interaction with other 
nuclear transcription factors, and homodimeric binding to 
specific deoxyribonucleic acid (DNA) sequences allow the 
regulation of gene transcription and protein synthesis [22, 
23]. In the airways and lungs, corticosteroids interact with 
the GCR following inhalation and absorption into airway 
mucosa and the tissues below.
Whereas most drugs have a narrow ‘therapeutic window’, 
corticosteroids can exert their effects over a broad concen-
tration range [25]. This is due to the existence of multiple 
mechanisms of action. Broadly, the steroid-activated GCR 
can be viewed as a ligand-regulated transcription factor, 
which controls a very diverse set of genes. Most actions 
of corticosteroids are mediated by the pleiotropic effects of 
GCRs on multiple signalling pathways [23, 26, 27]. Three 
major classes of action relevant for control of asthma and 
COPD have been described: (1) directly regulating the 
expression of inflammatory genes encoding cytokines, 
chemokines, adhesion molecules, inflammatory enzymes, 
receptors and proteins by binding to positive or negative 
glucocorticoid response elements (GRE); (2) binding to 
and sequestering other transcription factors, such as nuclear 
factor (NF)-ĸB; and (3) directing DNA three-dimensional 
histone protein binding architectures via the counterbal-
anced activity of histone acetyltransferases and histone 
deacetylases, thus regulating access to the transcriptional 
gene machinery [28].
basis for its development for asthma and eventual use in the 
treatment of COPD.
This clinical utility has given further impetus to the devel-
opment of newer inhaled corticosteroids (ICS), and FLU, 
fluticasone propionate (FP), ciclesonide (CIC), mometa-
sone furoate (MF), and fluticasone furoate (FF) have been 
approved since the introduction of beclometasone and bude-
sonide. These newer compounds were designed primarily for 
enhanced lipophilicity, which prolonged intraluminal airway 
retention time with the aim of achieving efficacy with once-
daily dosing. However, this approach also introduced poten-
tial issues around longer localised airway immunosuppres-
sion, potentially enhancing the risk of pneumonia and other 
respiratory infections [14]. The raised lipophilicity also 
prolongs the terminal half-life in the systemic circulation, 
which increases the risk of systemic adverse effects [15–17].
Today, ICS are recommended in guidelines as the cor-
nerstone of pharmacotherapy for patients with persistent 
asthma across all severities, and also in combination with 
a long-acting β2-agonist (LABA) for patients with moder-
ate to severe asthma [18]. ICS are considered by the Global 
Asthma Network guidance as the first-line asthma preven-
ter for patients with persistent or frequent symptoms, and 
in combination with LABA (ICS/LABA) are envisaged to 
have an ever-increasing role in the treatment of asthma [19]. 
Indeed, two ICS and one ICS/LABA combination are listed 
on the World Health Organization’s Model List of Essential 
Medicines [19]. Furthermore, they remain the only class of 
anti-asthma drug proven to reduce asthma deaths [20]. In 
COPD, ICS are recommended in combination with LABA 
by current guidelines for patients with moderate-to-very 
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Microarray analyses of cultured airway epithelial cells 
have enabled detailed mapping of genes affected by budeso-
nide treatment [29]. A single, high-dose budesonide inhala-
tion led to a ≥ 2-fold increase in the expression of 46 genes 
in bronchial biopsy samples within 6 h [30]. Upregulated 
genes included those inhibiting NF-κB and AP-1, the dual-
specificity phosphatase-1 that controls activated mitogen-
activated protein kinases (MAPK), and inhibitors of G-pro-
tein coupled receptors and T-cell chemotaxis. There were 
also 10 downregulated genes whose expression decreased 
by at least 50% following budesonide inhalation, includ-
ing genes for chemokines, metalloproteases and Toll-like 
receptors.
Another potential mechanism of action of ICS involves 
protection against oxidative or viral damage to the epithe-
lial barrier function. In cultured human epithelial cell lines, 
budesonide protected barrier function significantly more 
effectively than FP in response to cigarette smoke extract, 
possibly due to attenuation of epidermal growth factor 
receptor-dependent glycogen synthase kinase-3β phospho-
rylation [31].
However, there are also some faster, non-genomic mecha-
nisms that inhibit the production of mediators associated 
with inflammatory cells in the airways [22, 26], such as 
GCR-dependent inhibition of the MAPK pathway [32, 
33]. Rapid change in airway blood flow is a non-genomic 
parameter that reflects bronchial vascular response to ICS. 
Corticosteroids inhibit organic cation transporters (OCT), 
such as OCT-3, expressed by the vascular smooth mus-
cle cells, resulting in an increase of adrenergic agonists at 
α-adrenergic receptor sites [34]. ICS can therefore reduce 
the airway hyperaemia that is both a manifestation of inflam-
mation and a contributory factor to further inflammation. 
Budesonide has been shown to rapidly reduce airway hyper-
aemia, and was significantly more potent in this respect than 
BDP, and more potent than FP in asthmatic subjects in one 
comparative study [35].
2.2  Corticosteroid Chemical Structure–Activity 
Relationship
All corticosteroids consist of a hydrogenated cyclopentan-
operhydrophenanthrene ring system, with three cyclohexane 
rings and one cyclopentane ring [36] and a range of different 
substituents. It is the nature and position of these substitu-
tions that determine differences in their potency and clinical 
efficacy (Fig. 1) [37]. Key positions that affect potency are 
halogenation of the 6 and 9 positions [38], while R-sub-
stitution at the 16α and 17α positions affects lipophilicity. 
Also, R-substitution at the 17 position affects the glucocor-
ticoid potency. Budesonide is a non-halogenated ICS that 
has lipophilic substitutions at the 16α and 17α positions 
and a hydroxyl group at the C21 position (Fig. 1) [13, 38]. 
Pharmacological and metabolic studies have shown that the 
non-symmetrical acetal substitution in the 16α and 17α posi-
tions optimises the ratio of topical to systemic activity [12, 
38, 39]. After systemic uptake, budesonide’s non-symmet-
rical acetal group can be split by liver enzymes, resulting in 
metabolites with much lower receptor affinity, which does 
not occur to the same extent for the symmetrical acetals 
of the 16α,17α-acetonide glucocorticoids (e.g. FLU, TA) 
[40]. This, together with further biotransformation routes, 
improves the systemic tolerability of budesonide and enables 
dose escalation when required [41, 42].
2.3  Factors Affecting Lung Deposition
The clinical benefits of an inhaled therapy depend on drug 
particles being deposited in the airways/lungs, rather than 
swallowed or exhaled. Particles between 1–5 μm in diameter 
are the optimal size for deposition in the central and periph-
eral airways [45, 46]. If particles < 1 μm are not exhaled 
again [45], they may be deposited in the alveoli and rapidly 
absorbed into the systemic circulation [47, 48] while larger 
particles tend to impact on the oropharynx rather than reach-
ing the central or peripheral airways/lung [46]. Along with 
particle size, lung deposition also depends on factors such 
as the velocity at which the particles are delivered and, with 
the dry powder inhaler (DPI), the peak inspiratory flow rate 
and internal resistance of the device [46].
3  Development of Budesonide
In the 1960s, researchers at the Swedish pharmaceuti-
cal company Bofors Nobel-Pharma (a project later incor-
porated into Astra AB) designed a novel series of potent 
non-symmetrical 16α, 17α-acetal corticosteroids [12, 13]. 
Using new functional screening models for local selectivity, 
including human forearm skin blanching potency tests, the 
lead compound, budesonide, was found to have a topical 
selectivity several-fold better than BDP and other dermal 
steroids. The first patent application was filed in 1972 and 
budesonide was selected as a candidate drug by Astra AB in 
1974, with asthma as the primary indication. Positive initial 
study results led to the approval of budesonide in 1981 for 
daily maintenance treatment for asthma (Fig. 2) [49].
In the first studies in asthma, budesonide was delivered 
via a pressurised metered-dose inhaler (pMDI) [6, 50–55]. 
Dose-dependent improvements in peak expiratory flow 
(PEF) were demonstrated for daily doses of 400–1600 μg 
[6] and, during the 1990s, the results from studies with 
budesonide in asthma supported early intervention with ICS 
after initial onset of symptoms [56–58]. This was shown 
to improve asthma control and potentially to prevent pro-
gression to chronic irreversible airway obstruction [59, 60]. 
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These studies contributed to increased early use of ICS in 
asthma of all severities [58], and along with studies showing 
only small, transient effects on long-term growth in children 
[59, 61], were important factors in the recommendation of 
ICS as first-line therapy in asthma guidelines [37].
Also in the 1990s, advances in inhaler technology enabled 
greater efficiency of drug delivery. A comparison between 
the original suspension pMDI and the newly developed 
budesonide DPI, the  Turbuhaler®, found that lung depo-
sition was approximately doubled with the DPI, with less 
variability, and only 50% higher systemic availability than 
with the pMDI [62]. This allowed the same degree of asthma 
control to be achieved with a lower dose, and with a reduced 
risk of systemic adverse effects, thus making twice-daily 
dosing feasible. Dose-dependent improvements in lung func-
tion were observed in two 12-week, randomised, placebo-
controlled studies of budesonide  Turbuhaler® in adults [63] 
or children [64] with moderate-to-severe persistent asthma. 
Budesonide twice daily via  Turbuhaler® was significantly 
more effective than placebo, even at low doses (200 μg total 
daily dose), and was well tolerated in both studies. A nebu-
liser suspension  (Respules®) was subsequently developed 
for the treatment of very young children or other patients 
who were unable to use a handheld inhaler effectively [65].
Budesonide is currently available as a single-drug for-
mulation in the  Flexhaler® (in the US) or  Turbuhaler® DPI 
(outside of the US), in the  Respules® nebuliser suspension 
[65], and in combination with formoterol as a pMDI or 
DPI. Budesonide drug particles delivered via any of these 
technologies are within the optimal range of 1–5 µm [46]. 
Generic formulations are now available in some countries.
4  Properties of Budesonide
The development of ICS subsequent to budesonide aimed to 
improve once-daily efficacy by enhancing their lipophilic-
ity [66], which is postulated to prolong their intraluminal 
airway deposition [25] and dissolution time [22]. However, 
the advantage gained by longer airway immunosuppression 
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Fig. 1  The structures of inhaled corticosteroids [25]. Most ICS are 
administered as active compounds; however, beclometasone dipro-
pionate and ciclesonide are prodrugs that require conversion to the 
active state by on-site hydrolysis in airway/lung tissue. This is due to 
the fact they have a pre-existing ester at position C21. Ciclesonide is 
activated to desisobutyryl-ciclesonide (des-CIC), and beclometasone 
dipropionate to beclometasone-17-monopropionate (BMP) [43, 44]. 
Adapted with permission from Daley-Yates [25]
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introduces the potential for increased local adverse effects, 
which may also happen at a systemic level, as these agents 
have a long terminal half-life [16, 22]. As briefly reviewed 
in this section, budesonide’s pharmacokinetic/pharmacody-
namic properties make for a better balance between efficacy 
and safety than many of these newer ICS.
Budesonide is relatively less lipophilic, and hence more 
water soluble, than most other ICS [25, 67], which results in 
a shorter dissolution time in human bronchial fluid in vitro 
compared with other ICS (Table 1) [67, 71]. This allows it 
to enter the lung tissues quickly, minimising removal from 
the airways by mucociliary clearance or phagocytosis [67, 
72, 73]. In contrast, very low water solubility with, for exam-
ple, FF, MF and CIC (Table 1) prolongs the intraluminal 
dissolution time of these ICS and can extend their local 
anti-inflammatory efficacy [22]. However, such increased 
pulmonary residence time may also enhance the duration of 
the local immunosuppressive action of ICS in the airways/
lung. This may be particularly important in the presence of 
impaired mucociliary clearance and altered lung microbiome 
in COPD, potentially increasing the risk of pneumonia [74, 
75].
Absolute bioavailability, the drug taken up directly from 
airways/lung plus the swallowed and intestinally absorbed 
fraction bypassing the liver unmetabolised [22], is indicative 
of the potential for systemic distribution. Budesonide’s abso-
lute bioavailability is lower than that of BDP, and although 
it is greater than that of FLU, FP and MF (Table 2), several 
factors help to reduce the extent and duration of its systemic 
tissue absorption and its distribution. Firstly, it is cleared 
rapidly following systemic absorption—with a broadly 
similar clearance rate to FLU, FP and MF (Table 2) [22]. 
Secondly, ICS with higher lipophilicity have prolonged sys-
temic elimination; the relatively lower lipophilicity of bude-
sonide is thought to explain its shorter elimination half-life 
than that of FP, FF and MF (Table 1). Thirdly, in the sys-
temic circulation, higher lipophilicity also results in a higher 
volume of distribution (Vd) which, along with prolonged sys-
temic elimination, potentially results in drug accumulation 
in other body tissues and risk of more prolonged systemic 
exposure during repeated dosing (Fig. 3) [22, 37, 66, 76]. 
Budesonide’s moderate lipophilicity is associated with a 
smaller Vd than, for example, CIC, FP, MF and FF (Table 2; 
Fig. 3) and therefore with shorter systemic exposure, con-
tributing to a low risk of adverse events [15, 37, 39, 66].
4.1  Intracellular Pharmacodynamic Properties
After absorption into airway tissues, a considerable fraction 
of budesonide undergoes reversible intracellular esterifica-
tion to produce highly lipophilic fatty acids in an inactive 
depot form (mainly budesonide-21-oleate) [77]. This occurs 
via lipid conjugation of budesonide’s free hydroxyl group at 
carbon 21 (Fig. 4) [78]. Although lipid conjugation has also 
been observed with other ICS with a free hydroxyl group 
[22, 79], it is best documented for budesonide. As intracellu-
lar levels of free budesonide fall over time, these conjugates 
are hydrolysed by lipases, releasing more of the active drug 
to interact with the GCR [80]. It can be proposed that the 
esterification process therefore acts as a ‘sustained-release’ 
mechanism that prolongs lung residence time at the intra-
cellular target level [80, 81]. This explains budesonide’s 
high and extended local efficacy for a non-halogenated ICS 
with only moderate lipophilicity, in contrast with the more 
Fig. 2  Key milestones in the 
development of budesonide. 
COPD chronic obstructive 
pulmonary disease, DPI dry 
powder inhaler, pMDI pressur-
ised metered-dose inhaler
First patent
application filed
1972
First approval of
budesonide pMDI
for use in asthma
1981
First approval of
budesonide DPI for use
in adults with asthma
1988
First approval of
budesonide/formoterol
for use in asthma
2001
First approval of
budesonide/formoterol
for use in COPD
2008
Key studies of
budesonide
DPI in asthma
1994–1998
Selected as
candidate drug
1974
Studies of budesonide
pMDI in asthma
1980–1988
Studies of
budesonide
nebuliser solution
1988–1992
Key studies of
budesonide/
formoterol in COPD
2003
SYGMA studies of as-needed
budesonide/formoterol
as anti-inflammatory reliever
2018
Key studies of
budesonide/
formoterol
in asthma
1997–2001
Key studies of budesonide/
formoterol maintenance
and reliever therapy
in asthma
2004–2007
First approval of
budesonide nebuliser
solution for use in asthma
1992
First approval of
budesonide/formoterol maintenance
and reliever therapy for use in asthma
2012
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lipophilic ICS that are proposed to have extended airway 
residence due to their prolonged intraluminal dissolution 
time [77, 81]. Because the esterification process is driven by 
high budesonide concentrations, far fewer budesonide esters 
are formed within peripheral cells [78, 81, 82]. The ability 
of budesonide to undergo a reversible partial esterification 
preferentially within airway cells is thought to create the 
unique ability to have a higher lipophilicity at the target tis-
sue than when circulating in the body [78, 81, 83].
The binding affinity of ICS for the target GCR appears 
to be related to their lipophilicity, with budesonide having 
a considerably lower affinity than more lipophilic ICS such 
Table 1  Properties of ICS
GCR glucocorticoid receptor, ICS inhaled corticosteroids, NA not available in current literature, ND not determined, PR progesterone receptor
a Log p values are defined as the  log10 of the octanol/water partition coefficient
b Water solubility at 37 °C
c Relative receptor affinity with reference to a receptor affinity of dexamethasone of 100
d Active metabolite of beclometasone dipropionate
e Active metabolite of ciclesonide
Corticosteroid Lipophilicity 
(log P)a [25]
Water  solubilityb 
(μg/mL) [25, 67]
Dissolution time (human 
bronchial fluid in vitro) 
[67]
Half-life (h) [22] GCR binding 
 affinityc [22, 
25]
Selectivity for the 
GCR vs the PR 
[68]
Beclometasone  
dipropionate
4.59 0.13 > 5 h 0.1 53 NA
17-Beclometasone 
 monopropionated
3.27 15.5 ND 2.7 1345 9.3
Budesonide 2.32 16 6 min 2.8 935 44
Fluticasone propionate 3.89 0.14 > 8 h > 14 1775–1800 11.8
Fluticasone furoate [69] 4.17 < 0.1 NA 17–24 [70] 2989 ± 135 NA
Mometasone furoate 4.73 < 0.1 ND 4.5 2100–2200 1.1
Ciclesonide 3.2 < 0.1 ND 0.4 12 NA
Desisobutyryl- 
ciclesonidee
3.0 7 ND 3.6–5.1 1200 NA
Flunisolide [69] 1.36 140 NA 1.6 177 NA
Table 2  Pharmacokinetic properties of ICS
ICS inhaled corticosteroids, NA not available in current literature, MDI metered-dose inhaler, ND not determined
*Hydrofluoroalkane propellant MDI
# Dry-powder inhaler
† Apparent maximum approximation based on complete conversion of the parent compound
a Determined in healthy subjects
b Active metabolite of beclometasone dipropionate
c Active metabolite of ciclesonide
Corticosteroid Absolute  bioavailabilitya 
(%) [25]
Clearance (L/h) [22, 
25]
Volume of distribution (L) 
[22, 25]
Protein-
binding (%) 
[22, 25]
Beclometasone dipropionate 82* 120–230 20 87–96
17-Beclometasone  monopropionateb ND 120† 424† NA
Budesonide 39# 84 180–183 88–91
Fluticasone propionate 16# 69 318 90–99
Fluticasone furoate [69] 15# 65 608 99
Mometasone furoate 11# 54 332 98–99
Ciclesonide 63* 152–228 207–396 99
Desisobutyryl-ciclesonidec ND 396† 1190† 99
Flunisolide [69] 70* 58 96 61–80
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as MF, FP or FF (Table 1) [22]. However, a highly lipophilic 
inhaled ICS extends local tissue binding and GCR triggering 
[71], but when further distributed into the systemic circula-
tion it may worsen the risk:benefit ratio due to its greater and 
longer systemic exposure [22].
Although budesonide has a lower GCR binding affinity, it 
offers the advantage of greater selectivity for the GCR versus 
the PR as compared with some other ICS (at least according 
to one study; Table 1); differences in GCR selectivity may be 
inversely related to lipophilicity [68]. This greater GCR ver-
sus PR selectivity may help avoid further systemic adverse 
effects, particularly at higher doses, when it is thought ICS 
may then also bind to the PR, which has a similar binding 
domain to the GCR [68].
4.2  Pharmacodynamic Rationale for ICS/
Long‑Acting β2‑Agonist (LABA) Combination 
Therapy
Numerous potential intracellular mechanisms of synergis-
tic interaction between corticosteroids and β2-agonists have 
been identified [85]. Synergy has proved difficult to confirm 
in vivo, although additive effects have been demonstrated 
[41, 86–90], providing a rationale for the combination of 
ICS and LABA for the treatment for asthma and COPD [85, 
87, 91, 92]. Indeed, corticosteroids bind to a positive GRE 
and increase the gene transcription of β2-adrenoceptors in 
human lung tissue in vitro [93], thus increasing the expres-
sion of β2-receptors and protecting against their down-
regulation and G-protein adenylyl cyclase uncoupling after 
long-term administration of β2-agonists [94–97]. There is 
also some evidence of activation of the GCR by β2-agonists 
which augments translocation of the bound GCR into the 
nucleus and may mediate the anti-inflammatory effect of 
ICS in vitro and in vivo [98, 99]. In addition, there is also 
evidence of ‘coincident pharmacology’ for ICS and LABA, 
resulting from a higher co-deposition on the same cells with 
the combined inhaler [85, 100]. This is supported by evi-
dence of augmented ICS-induced GCR nuclear translocation 
in airway cells when an ICS is administered in combination 
with a LABA [98].
5  Budesonide Studies in Asthma
An abundance of data exists concerning budesonide treat-
ment in patients with all severities of asthma. Budesonide 
600 µg twice daily (bid) was compared with terbutaline 
375 µg bid over 2 years in patients in whom asthma had 
appeared within the previous year [56]. Forced expiratory 
volume in one second  (FEV1), morning and evening PEF 
and asthma symptoms all improved with budesonide versus 
terbutaline, and the budesonide group also needed less ‘res-
cue’ terbutaline. These results supported early use of bude-
sonide in newly detected asthma. A 1-year follow-up study 
to investigate the effect of reducing or discontinuing the 
steroid dose [57] from 1200 to 400 µg found that, compared 
with placebo, the lower budesonide dose maintained reduced 
bronchial hyperresponsiveness to histamine in 74% versus 
33% of patients, with significant differences also seen in pul-
monary function. A 2-year study with budesonide 400 µg bid 
and a 12-month study of early intervention with low-dose 
(200 µg bid) budesonide also supported early treatment with 
an ICS [60, 101]. Low maintenance doses of budesonide 
100–200 µg bid have also proved effective in reducing severe 
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exacerbations and improving asthma control in patients with 
mild asthma [102].
The dose-dependent nature of budesonide’s clinical effi-
cacy was elucidated in a 12-week study in patients with 
moderate-to-severe asthma published in 1998 [63]. Bude-
sonide was administered twice daily at a total dose of 200, 
400, 800 or 1600 µg. The effects on PEF and  FEV1 were 
significantly greater with the 1600-µg dose than with the 
200-µg dose, although not for the other doses studied. Flex-
ible dosing with budesonide has also been investigated in 
patients with mild asthma [103]. Subjects were randomised 
to budesonide 200 µg bid, BDP 250 µg bid or non-steroidal 
treatment for 2 years, with the ICS dose adjusted accord-
ing to asthma severity and treatment response. The patients 
receiving ICS had a more rapid and marked increase in  FEV1 
and morning PEF compared with non-steroidal treatment, 
with the changes inversely correlated to mean ICS dose 
(p < 0.001).
The efficacy of budesonide in children has been inves-
tigated in several studies, notably the long-term Steroid 
Treatment As Regular Therapy (START) and the Childhood 
Asthma Management Program (CAMP) trials [104, 105]. 
The START study included 7241 patients, over a quarter 
of whom were children younger than 11 years [105]. Daily 
doses of budesonide 400 µg, or 200 µg for children, were 
compared with placebo. Budesonide significantly reduced 
the risk of a first severe asthma-related event by 44% (hazard 
ratio 0.56, 95% CI 0.45–0.71; p < 0.0001). There were also 
significant increases in pre- and post-bronchodilator  FEV1 
and symptom-free days compared with placebo, supporting 
the use of long-term treatment with once-daily, low-dose 
budesonide in patients with recent-onset mild asthma. The 
CAMP study compared the efficacy of budesonide 200 µg 
bid and nedocromil sodium 8  mg bid with placebo for 
4–6 years in 1041 children with mild-to-moderate asthma 
[104]. Budesonide treatment did not significantly increase 
post-bronchodilator  FEV1, although there were significant 
improvements in asthma symptoms, use of rescue medica-
tion, number of episode-free days and airway responsiveness 
to methacholine compared with placebo (p ≤ 0.01). Efficacy 
has also been shown with nebulised budesonide  (Pulmicort® 
 Respules®) in children with steroid-dependent, persistent 
asthma [65].
6  Budesonide Studies in COPD
In the European Respiratory Society study on COPD 
(EUROSCOP), twice-daily budesonide 400 µg adminis-
tered via DPI was compared with placebo over 3 years in 
patients with mild COPD who continued smoking [106]. 
The primary endpoint, change in post-bronchodilator  FEV1, 
improved with budesonide treatment in the first 6 months of 
the study, but the changes from 9 months to the end of treat-
ment were not significantly different. The median decline in 
 FEV1 over 3 years was 140 mL in the budesonide group and 
180 mL with placebo (p = 0.05); or 4.3% and 5.3% of the 
predicted values, respectively (p = 0.04).
Nebulised budesonide has also been studied in COPD 
patients. In one study, budesonide 2 mg every 6 h for 72 h 
delivered by  Pulmicort®  Respules® was compared with oral 
prednisolone 30 mg every 12 h and placebo for the treat-
ment of acute COPD exacerbations. Improvements in post-
bronchodilator  FEV1 over 72 h were greater in both treat-
ment groups versus placebo (budesonide versus placebo, 
0.10 L [0.02–0.18]; prednisolone versus placebo, 0.16 L 
[0.08–0.24]), suggesting that nebulised budesonide could 
have value in treating acute COPD exacerbations [107].
7  Budesonide/Formoterol Studies 
in Asthma
Treatment with budesonide in combination with the fast-
acting LABA, formoterol, has been extensively investigated 
in patients with asthma. In the FACET (Formoterol and Cor-
ticosteroids Establishing Therapy) study, the addition of 
formoterol to budesonide via separate inhalers significantly 
reduced mild and severe exacerbations compared with bude-
sonide alone (p < 0.01). Mean symptom scores and rescue 
medication use were also significantly improved (p < 0.001) 
[90]. Similar results were obtained when patients received 
twice-daily maintenance therapy with budesonide/formo-
terol from a single inhaler [108]. A large real-world study 
using a retrospective matched cohort population database 
analysis showed lower rates of exacerbation and healthcare 
utilisation with the budesonide/formoterol combination 
than with salmeterol/fluticasone in asthma [109]. This com-
bination treatment was first approved for use in asthma in 
2001 and is currently available in a choice of pMDI or DPI 
devices. Budesonide/formoterol by DPI is also potentially 
suitable for once-daily dosing in patients with asthma, due 
to the long duration of action of both mono-components 
[81, 110].
8  Budesonide/Formoterol Studies in COPD
The budesonide/formoterol combination has also been 
investigated in patients with COPD. In two large, 12-month 
studies, twice-daily treatment with budesonide/formoterol 
320/9 μg1 delivered via DPI reduced the mean number of 
1 Delivered dose, corresponds to a budesonide/formoterol metered 
dose of 400/12 μg.
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severe exacerbations versus all comparators (p < 0.05 ver-
sus formoterol) [111, 112], leading to the approval of this 
treatment in 2008 (not via DPI in the USA) for patients 
with COPD and a history of repeated exacerbations. In the 
12-month SUN study [113], the higher strength budesonide/
formoterol pMDI formulation (160/4.5 µg2 bid) improved 
pre-dose  FEV1 and prolonged time to first COPD exacer-
bation versus formoterol (p = 0.008 and p = 0.026, respec-
tively). Both budesonide/formoterol formulations (160/4.5 
and 80/4.5 µg3 bid) reduced the overall number of exacer-
bations per patient-treatment year versus formoterol (25% 
and 29%, respectively; p ≤ 0.004). In the 6-month SHINE 
study [114], greater improvements in pre-dose  FEV1 and 
1-h post-dose  FEV1 were observed with budesonide/for-
moterol 160/4.5 µg bid pMDI versus the primary compara-
tors of formoterol (p = 0.026) and budesonide (p < 0.001), 
respectively. The recent RISE study compared budesonide/
formoterol pMDI 320/9 µg bid with formoterol DPI 9 µg 
bid for 6 months in patients with moderate-to-very-severe 
COPD and a history of exacerbations [115]. Both the annual 
rate of moderate and severe exacerbations and the time to 
first exacerbation were significantly reduced with bude-
sonide/formoterol treatment versus formoterol alone. The 
pMDI formulation of budesonide/formoterol 320/9 μg was 
approved by the US FDA for COPD in 2009 and for reduc-
tion of COPD exacerbations in 2017.
A number of other ICS/LABA DPI combination treat-
ments have been approved for use in patients with COPD, 
but direct comparisons between these treatments are lim-
ited. In the retrospective, observational PATHOS study in 
matched patients with COPD, budesonide/formoterol was 
shown to significantly reduce the exacerbation rate versus 
salmeterol/FP (0.80 vs 1.09 exacerbations per patient-year) 
[116]. All other adverse healthcare outcomes were also 
significantly reduced with budesonide/formoterol. Similar 
results had been observed in another matched cohort popu-
lation-based study in patients with COPD [117].
Due to the fast onset of bronchodilation with formoterol 
[118], budesonide/formoterol combinations can also be of 
benefit in patients with severe COPD who experience their 
worst symptoms in the early morning when lung function 
is at its lowest ebb, due to diurnal variation. In one study, 
short-term treatment with budesonide/formoterol 320/9 μg 
bid resulted in a significantly greater improvement in ability 
to perform morning activities (p < 0.05) than with salmet-
erol/fluticasone propionate 50/500 μg bid [119]. The CLIMB 
study showed that 12 weeks’ treatment with the same dose of 
budesonide/formoterol and the addition of tiotropium 18 µg 
once daily resulted in rapid and sustained improvements in 
morning lung function, symptoms, reliever use and activi-
ties and a 62% reduction in exacerbations versus tiotropium 
alone [120]. Interestingly, budesonide has been found to 
enhance the fast onset of action of formoterol in patients 
with stable COPD, possibly due to non-genomic actions that 
can occur within a few minutes [121].
9  Budesonide/Formoterol as Both 
Maintenance and Reliever Therapy 
in Asthma
Formoterol has a fast onset of bronchodilator effect simi-
lar to salbutamol [118], and although the bronchodilator 
effects last much longer than salbutamol, systemic effects 
are equally short-lived [122]. This enables more flexibility of 
dosing with a budesonide/formoterol combination than other 
ICS/LABA combinations where the LABA has a slower 
onset of effect and more prolonged systemic effects. The 
high water solubility and moderate lipophilicity of budeson-
ide leads to dissolution in airway lining fluid within minutes, 
and subsequent rapid absorption into airway/lung tissue [22, 
123]. One study has shown that, within 2 h of administration, 
a bolus dose of inhaled budesonide reverses subsensitivity 
to adenosine monophosphate bronchoprotection and asso-
ciated down-regulation of lymphocyte β2-adrenoreceptors 
produced by regular formoterol treatment in patients with 
asthma [95]. The results from this study support the use of 
additional bolus doses of inhaled corticosteroids in conjunc-
tion with β2-agonists for the treatment of acute episodes of 
bronchoconstriction.
The use of budesonide/formoterol as an as-needed 
reliever with anti-inflammatory properties in addition to 
maintenance therapy provides an alternative to higher main-
tenance doses of ICS alone, and enables earlier, symptom-
led intervention with ICS when patients experience worsen-
ing symptoms, potentially preventing the development of 
exacerbations (Fig. 5) [124, 125]. Regulatory approval out-
side of the US has been given for the budesonide/formoterol 
combination in a single DPI to be used in this way. This is 
a valuable additional approach to asthma management that 
fits in with how most patients actually behave, increasing 
reliever use when symptoms worsen [126, 127], whilst giv-
ing clinicians the reassurance that their patients will also 
receive an anti-inflammatory dose of budesonide with every 
dose of reliever.
To evaluate the specific contribution of as-needed bude-
sonide/formoterol as a reliever against a background of 
maintenance therapy, the efficacy of three reliever strate-
gies was investigated [128]. Patients with moderate to severe 
persistent asthma remaining symptomatic on budesonide/
2 Delivered dose, corresponds to a budesonide/formoterol metered 
dose of 200/6 μg.
3 Delivered dose, corresponds to a budesonide/formoterol metered 
dose of 100/6 μg.
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formoterol maintenance therapy received terbutaline, for-
moterol or budesonide/formoterol as reliever medications 
for 12 months. Interestingly, both mono-components were 
shown to be important when given as needed in addition to 
budesonide/formoterol maintenance therapy, with formo-
terol reducing severe exacerbations to a greater extent than 
terbutaline. However, greater reductions in severe exacer-
bations were observed with budesonide/formoterol as both 
maintenance and reliever compared with formoterol as an 
as-needed reliever therapy on top of budesonide/formoterol 
maintenance treatment [128].
10  Safety
Inhaled corticosteroids have been associated with a risk of 
certain adverse events, such as pneumonia, oropharyngeal 
Candida infection and lower respiratory tract infections such 
as tuberculosis and non-tuberculous mycobacterioses. This 
is potentially due to immunosuppressive effects resulting 
from the relatively high local concentrations of these medi-
cations in the airways/lung [14, 129–132]. Systemic adverse 
effects can include reductions in bone mineral density 
(BMD), adrenal suppression, cataracts, and glaucoma [17, 
103], as well as skin bruising [133]. A number of clinical 
trials and long-term studies have assessed the safety profile 
of budesonide and found the risk:benefit ratio to be favour-
able, both in asthma and COPD [39, 106, 134].
10.1  Safety in Asthma
In an analysis of asthmatic patient data from The Health 
Improvement Network database, budesonide use was asso-
ciated with a small increase (odds ratio (OR) 1.20, 95% 
CI 1.06–1.35; p = 0.003) in the risk of pneumonia or a 
lower respiratory tract infection (LRTI), while the risk of 
these events was much greater with FP (OR 1.64, 95% CI 
1.50–1.79; p < 0.001) [129]. In the START study (n = 7241) 
of early intervention in mild asthma, the frequency of infec-
tions was similar between budesonide and placebo (38.5% vs 
38.3%) [39, 105], as was the incidence of tuberculosis (0.1% 
for placebo and 0.3% for budesonide) [39, 134].
The association of OCS with the development of osteo-
porosis is well documented, but the effect of ICS on bone 
metabolism and bone density is less clear [103]. In a long-
term study of inhaled budesonide in children with asthma, 
there were no adverse effects on BMD, total bone calcium, 
total body bone mineral capacity or body composition after 
3–6 years of treatment. The mean daily budesonide dose was 
504 μg, and there was no correlation between duration of 
treatment and bone density parameters [135]. When changes 
in BMD were compared between ICS and non-ICS treat-
ments over 2 years in adults with mild asthma, no significant 
differences were observed between budesonide, BDP or a 
non-steroid reference treatment [103]. There was a correla-
tion between ICS dose and a reduction in BMD at the lumbar 
spine over the 2-year study, possibly due to a direct effect on 
bone or to an indirect effect related to asthma severity, but 
overall the data suggest that low to moderate doses of ICS 
have little effect on BMD over 2 years. A 1-year, open-label 
study in 59 adult patients with moderate-to-severe asthma 
reported no significant difference between high-dose bude-
sonide and high-dose FP in BMD, and no significant decline 
in BMD overall [136].
The systemic potency of ICS can be measured by their 
effects on the hypothalamic–pituitary–adrenal (HPA) axis, 
and a number of long-term trials have studied this [39]. HPA 
axis function was one of the safety endpoints in a 52-week, 
open-label study of budesonide (100–800 µg bid) in adults 
and children [137]. There was no evidence of any suppres-
sion in function, as both basal and stimulated plasma cortisol 
levels were maintained throughout the study. These results 
were reflected in two further studies in children on long-
term budesonide treatment, with one study even showing 
improvements in adrenal function with budesonide over 
6–12 months [138, 139]. Budesonide has also been shown 
to have a minimal effect on serum cortisol levels and bone 
turnover in comparison with microgram-equivalent doses 
of FP [17, 140–143].
A long-term study of children with mild-to-moderate 
asthma by the CAMP Research Group assessed the effect 
of ICS on lung function and growth over 4–6 years [104]. 
Children receiving budesonide 200 µg bid showed no sig-
nificant difference in lung function versus placebo at 4 years, 
as measured by change in post-bronchodilator  FEV1, despite 
an improvement at 1 year. The budesonide group showed a 
small, transient reduction in growth velocity versus placebo, 
primarily evident within the first year. However, growth 
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Fig. 5  Illustration of outcomes with different asthma treatment regi-
mens in response to worsening symptoms [124]. Reproduced with 
permission from Ankerst [124]
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velocity was similar by the end of the treatment period, and 
changes in bone density and end-of-treatment bone age, 
projected final height and Tanner stage were all similar to 
placebo. The growth velocity findings were supported by 
an 18-month study of continuous low-dose budesonide or 
continuous budesonide for 6 months then as needed [144]. 
A small initial decline in growth velocity with both budeso-
nide treatment regimens normalised by the end of the trial, 
with budesonide as-needed associated with catch-up growth. 
No long-term adverse effects on growth velocity or weight 
gain were seen in further studies in asthmatic children with 
daily budesonide doses of up to 400 µg [59]. While a meta-
analysis in children with mild-to-moderate persistent asthma 
found greater reductions in 1-year mean linear growth veloc-
ity with budesonide than with several other ICS (CIC, FLU, 
FP and MF) using indirect comparison methods, the differ-
ences were small (− 0.59 versus − 0.08 to − 0.47 cm/year) 
and their clinical relevance was not clear [145].
Other systemic adverse effects linked to the long-term use 
of high-dose ICS include cataracts, glaucoma, and ocular 
hypertension [17]. However, two studies in children with 
asthma found no increase in occurrence of posterior subcap-
sular cataracts versus controls after up to 6 years’ treatment 
with budesonide [104, 146].
Data from large-scale retrospective studies have shown 
that treatment with anti-asthmatic medications can increase 
the risk of pregnancy complications and low infant birth 
weight [147, 148], although budesonide-specific data have 
not shown a significant increase in congenital malformations 
[39, 149]. A study in pregnant mice showed less transpla-
cental transfer of free budesonide than of free FP [150]. This 
appeared to depend on the lower lipophilicity of budesonide 
and the fact that, as a substrate for P-glycoprotein, budeson-
ide can be transported out of the placenta and brain.
10.2  Safety in COPD
An increased incidence of pneumonia in COPD patients 
receiving ICS treatment has been observed in several stud-
ies, although there are indications of intra-class differences 
in risk [75, 151, 152]. Recent studies in human bronchial 
epithelial cells have shown that treatment with budesonide 
results in significantly higher expression of specific immune 
defence genes, and greater airway epithelial barrier protec-
tion against cigarette smoking and viral infection, than treat-
ment with FP [31, 75, 153]. Due to its greater lipophilicity 
and tenfold higher immunosuppressant potency, the pro-
longed residency time of FP in the airway epithelial lining 
fluid compared with budesonide may result in an increased 
duration of local immunosuppression and impaired path-
ogen clearance from the airways [14, 75, 154]. Addition-
ally, very recent work has demonstrated a differential 
response to budesonide compared with FP in blood-derived 
macrophages in smokers and ex-smokers with COPD [155]. 
Budesonide counteracted reductions in bacterial recognition 
receptors on monocyte-derived macrophages by both non-
typeable Haemophilus influenzae and Streptococcus pneu-
moniae, whereas FP only counteracted some of the reduc-
tions by S. pneumoniae. These differences may provide a 
greater understanding of mechanisms by which patients 
taking fluticasone-based preparations for COPD tend to be 
more susceptible to pneumonia [14]. The European Medi-
cine Association’s Pharmacovigilance Risk Assessment 
Committee reviewed the known risk of pneumonia with 
ICS in 2016 and concluded that, although COPD patients 
treated with ICS are at increased risk of pneumonia, the 
benefits of ICS continue to outweigh their risks [156]. In a 
population-based cohort study of patients with COPD, bude-
sonide was associated with a comparatively much lower risk 
of pneumonia (17% increased risk with no dose-response 
effect) than FP (dose-dependent increase, with the 1000-μg 
dose associated with a 122% increase in risk) or other ICS 
(primarily BDP) [74]. A meta-analysis of 43 studies made 
indirect comparisons of budesonide and fluticasone mono-
therapy and found a higher risk of any pneumonia event 
with fluticasone than with budesonide (OR 1.86, 95% CI 
1.04–3.34), although between-group differences were not 
significant for non-fatal serious adverse pneumonia events 
or mortality [157]. The authors cautioned interpretation of 
these results due to the quality of evidence and the indirect 
nature of the comparison [157]. In the FULFIL study, the 
rate of pneumonia in patients with COPD was lower with 
twice-daily budesonide/formoterol than with a once-daily 
triple therapy of fluticasone furoate/umeclidinium/vilanterol 
(FF/UMEC/VI) [158]. The incidence of pneumonia, a pre-
specified adverse event of special interest, over 24 weeks in 
the intention-to-treat population was 2.2% with FF/UMEC/
VI versus 0.8% with budesonide/formoterol. Additionally, in 
the PATHOS study, budesonide/formoterol was associated 
with a significantly lower rate of pneumonia and hospital 
admission for pneumonia (both p < 0.001) than salmeterol/
FP in matched cohorts of patients with COPD [14]. The 
risk of pneumonia was not associated with the dose of ICS 
received for either treatment. The 6-month KRONOS trial 
showed similar rates of confirmed pneumonia (2%) for both 
budesonide/glycopyrrolate/formoterol and glycopyrrolate/
formoterol [159].
A meta-analysis of seven large clinical studies con-
cluded that treatment with budesonide for 12 months does 
not increase the risk of pneumonia in patients with COPD 
as compared with control (formoterol or placebo) [160]. 
A subsequent meta-analysis that included an eighth large 
trial found that the incidence of pneumonia increased with 
increasing severity of airflow limitation, both for patients 
who received budesonide and those on non-ICS con-
trols [161]. However, although this further trial showed a 
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significantly increased pneumonia incidence with bude-
sonide/formoterol compared with formoterol alone, when 
these data were added to the pooled data from the seven 
trials, no significantly increased risk of pneumonia with 
budesonide was noted [162]. Although the overall risk for 
pneumonia increased with COPD severity, there was no 
difference in pneumonia risk with budesonide treatment in 
any Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) severity group. In the RISE study, the incidence 
of protocol-defined pneumonia or LRTI adverse events was 
numerically lower with budesonide/formoterol (pneumonia, 
0.5%; LRTI, 1.5%) than with formoterol alone (pneumo-
nia, 1.0%; LRTI, 3.3%) [115]. No patients in the budeson-
ide/formoterol group experienced pneumonia as a serious 
adverse event, compared with 0.8% of patients in the formo-
terol group. A pooled analysis of 11 interventional studies, 
which included > 10,000 patients, compared the difference 
in pneumonia risk between inhaled budesonide-containing 
and non-budesonide-containing treatments [163]. The risk 
of pneumonia treatment-emergent adverse events (TEAEs) 
or serious adverse events (TESAEs) was not significantly 
increased with budesonide-containing compared with non-
budesonide-containing treatments (pooled HR 1.13 and 
1.15, respectively). The annual incidence rates with budeso-
nide- and non-budesonide-containing products were similar 
(5.2% vs 4.6%, respectively, for TEAEs and 1.9% vs 1.5% 
for TESAEs).
As in asthma, changes in BMD have also been observed 
in clinical trials in COPD patients. In the 3-year, placebo-
controlled EUROSCOP study, budesonide 400 µg bid had no 
significant effect on BMD, apart from a small positive effect 
on femoral trochanter bone density yearly decline (0.04% 
for budesonide vs 0.38% for placebo; p = 0.02) [106]. The 
12-month SUN trial found small but significant decreases 
in total lumbar spine and total hip BMD with budesonide/
formoterol 320/9 µg versus formoterol 9 µg, as seen on dual 
energy X-ray absorptiometry (DEXA) scans, but the clini-
cal relevance of these findings was unclear [113]. Of note, 
ophthalmology assessments were also performed in the SUN 
trial, including intraocular pressure and lenticular opacities. 
Similar minor increases in these parameters were observed 
across all treatment groups. Budesonide/formoterol 320/9 µg 
was associated with a small increase from baseline in poste-
rior subcapsular score compared with budesonide/formoterol 
160/9 µg (p = 0.022), but other clinically significant ophthal-
mological changes were infrequent [113].
11  The Future Role of ICS in Airways Disease
Historically, ICS clinical trials have not been selective for 
specific asthma phenotypes. However, current guidelines 
acknowledge asthma as a heterogeneous condition, with 
several phenotypes now recognised. The treatable allergic 
asthma phenotype is often associated with an eosinophilic 
airway inflammation endotype. These patients usually 
respond well to ICS treatment, and treatment guided by 
sputum eosinophil count is associated with a reduced risk 
of exacerbations compared with guidelines-based treatment 
[18]. Existing biomarkers such as blood eosinophil count, 
levels of nitric oxide in exhaled breath (FeNO) and serum 
immunoglobulin E, in addition to developments in new bio-
markers and tools for personalised medicine, will play an 
increasing role in asthma management in the future [164].
The use of ICS/LABA combination therapy in patients 
with asthma is evolving. While it has traditionally been 
viewed as controller therapy, the potential of using this 
combination alone as an as-needed reliever in mild asthma 
has now been investigated in the two SYGMA (SYmbicort 
Given as needed in Mild Asthma) studies [165, 166]. In 
SYGMA 1, the severe exacerbation rate was reduced by 
64% with as-needed budesonide/formoterol versus terbuta-
line (annualised exacerbation rates 0.07 and 0.20, respec-
tively; rate ratio (RR) 0.36), and was not significantly dif-
ferent from that of budesonide maintenance plus as-needed 
terbutaline as reliever (annualised exacerbation rates 0.07 
and 0.09, respectively; RR 0.83). Superiority to terbutaline 
and equivalence to budesonide maintenance plus terbutaline 
were also seen in time to first severe exacerbation. Gluco-
corticoid exposure was substantially lower with as-needed 
budesonide/formoterol than with budesonide maintenance in 
both studies: the median metered daily ICS dose was 83% 
lower in the budesonide/formoterol group compared with 
the budesonide maintenance group in SYGMA 1 (57 µg and 
340 µg, respectively) and 75% lower in SYGMA 2 (66 µg 
and 267 µg, respectively). Together, the SYGMA studies 
showed that as-needed budesonide/formoterol was supe-
rior to as-needed short-acting β2-agonist (SABA) alone for 
asthma symptom control and exacerbation risk reduction in 
mild asthma. The 2019 update to the Global Initiative for 
Asthma (GINA) report now recommends use of as-needed 
ICS/formoterol for patients on treatment step 1, replacing 
SABA as first-line reliever for safety reasons, because SABA 
has no anti-inflammatory effect and may in fact worsen 
eosinophilic airway inflammation [167].
GINA now proposes that asthma patients move from as-
needed ICS/formoterol only as a reliever up to ICS/formo-
terol as both maintenance therapy and as-needed reliever 
therapy, providing a treatment continuum across the spec-
trum of mild to moderate to severe asthma, with inherent 
flexibility of dosing and symptom control [167]. Hence, 
patients may intuitively step up and step down according to 
asthma control in a personalised flexible dosing regimen—
in other words, use more when needed and less when not 
(Fig. 6).
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Budesonide/formoterol is currently the only ICS/LABA 
licenced for this type of use, although this was because these 
components were well suited to each other in terms of their 
rapid uptake and short latency time, whereas most later ICS/
LABA combinations were aimed instead at a longer duration 
of action. By always assuring concordance between budeso-
nide and formoterol in this way, patients will automatically 
receive their ICS whenever they feel the need to take their 
reliever therapy. This is not the case with fixed-dose admin-
istration of combination ICS/LABA plus SABA reliever 
regimens, where many patients may stop or adhere poorly 
to their ICS/LABA and over-rely on their SABA reliever 
[168, 169].
As in asthma, ICS have generally only been tested in a 
broad COPD population. However, high levels of periph-
eral blood eosinophils have been reported in a significant 
proportion of patients with COPD [170], and appear to be 
predictive of clinical benefit from ICS or ICS/LABA. They 
may, therefore, have utility in determining which patients 
with COPD should receive ICS as part of their treatment 
regimen [21, 170, 171].
Some patients with advanced COPD benefit from triple 
therapy with an ICS/LABA in combination with a long-act-
ing muscarinic antagonist, and this approach is one of the 
suggested treatment pathways in the latest GOLD guidelines 
for Group D patients experiencing further exacerbations 
[21]. The TRIBUTE study showed an overall 15% reduc-
tion in moderate to severe exacerbations and no increase in 
pneumonia with beclometasone/formoterol/glycopyrronium 
versus indacaterol/glycopyrronium [172]. The IMPACT 
study showed 15% and 25% reductions in exacerbations with 
fluticasone furoate/umeclidinium/vilanterol compared with 
fluticasone furoate/vilanterol and umeclidinium/vilanterol, 
respectively. There was a 53% higher risk of pneumonia 
with triple therapy versus umeclidinium/vilanterol, and a 
similarly increased pneumonia risk with fluticasone furoate/
vilanterol [173]. The KRONOS study in moderate to very 
severe COPD (mostly GOLD group B) showed significantly 
improved  FEV1 area under the concentration-time curve 
from 0 to 4 h (AUC 0–4) with budesonide/glycopyrrolate/
formoterol treatment compared with budesonide/formoterol 
pMDI and DPI dual combination therapies (both p < 0.0001) 
[159]. The change from baseline in morning pre-dose trough 
 FEV1 was also significantly improved with triple therapy 
compared with glycopyrrolate/formoterol (p = 0.0139) and 
budesonide/formoterol pMDI and DPI (both p < 0.0001). 
Furthermore, there were significant improvements in sec-
ondary lung function endpoints compared with budeson-
ide/formoterol, as well as a 52% reduction in moderate or 
severe exacerbations compared with glycopyrrolate/formo-
terol (model-estimated annual RR 0.48, 95% CI 0.37–0.64; 
p < 0.0001). Pneumonia incidence was low (< 2%) and simi-
lar across treatments [159].
12  Conclusions
Many patient-years of clinical experience have been accu-
mulated with budesonide, providing a wealth of evidence of 
its efficacy and safety profile. Its molecular structure gives 
budesonide unique pharmacokinetic and pharmacodynamic 
properties that differentiate it from other ICS. The relatively 
low lipophilicity and high water solubility of budesonide 
compared with other ICS allows quicker absorption into lung 
tissue. The resultant lower volume of distribution, combined 
with a rapid systemic elimination, is responsible for the low 
risk of adverse events observed with budesonide in clinical 
use. The differentiating ability of budesonide to undergo a 
partial esterification of its free hydroxyl group at carbon 
21 increases lipophilicity at the target tissue, prolonging its 
duration of action at the GCR and extending its airway effi-
cacy and selectivity [83, 174].
Among current ICS, budesonide is the most versatile due 
to its dose-response relationship, including the possibility of 
administration by nebulisation to infants or the infirm elderly 
and in an intensive-care setting. Budesonide as a single-drug 
formulation has proven efficacious as maintenance therapy 
in both adults and children across a range of asthma severi-
ties, with positive results in studies with early intervention, 
low-dose and flexible-dose regimens. Increased efficacy 
with the addition of formoterol via a separate inhaler was 
followed by the introduction of fixed-combination budeso-
nide and formoterol. The fast onset of bronchodilator action 
with formoterol, combined with the favourable pharmacoki-
netic properties of budesonide, makes this combination well 
suited for as-needed use with or without regular maintenance 
therapy in patients with asthma. This approach ensures treat-
ment with ICS as soon as symptoms worsen. The fast and 
effective symptom relief provided by budesonide/formoterol 
is also of benefit to patients with COPD, improving their 
ability to perform morning activities while the sustained 
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effects improve breathlessness throughout the day with 
twice-daily dosing [119]. In addition, budesonide may be 
associated with a lower risk of pneumonia than FP or FF in 
patients with COPD [74].
The recent SYGMA studies showed the superior efficacy 
of as-needed budesonide/formoterol to as-needed SABA in 
terms of reducing the risk of exacerbation and improving 
symptom control in mild asthma. With comparable reduc-
tions in exacerbations to budesonide maintenance therapy, 
but with a lower ICS treatment load and no clinically rele-
vant difference in asthma control, the results support the use 
of a reliever with anti-inflammatory properties as a flexible 
and intuitive treatment for mild asthma that accommodates 
the typical behaviour patterns of patients and improves the 
benefit:risk ratio of asthma treatment.
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